Show simple item record

dc.contributor.authorEaston, Douglasen
dc.contributor.authorPharoah, Paulen
dc.contributor.authorAntoniou, Antonisen
dc.contributor.authorTischkowitz, Marcen
dc.contributor.authorTavtigian, Sean Ven
dc.contributor.authorNathanson, Katherine Len
dc.contributor.authorDevilee, Peteren
dc.contributor.authorMeindl, Alfonsen
dc.contributor.authorCouch, Fergus Jen
dc.contributor.authorSouthey, Melissaen
dc.contributor.authorGoldgar, David Een
dc.contributor.authorEvans, Gareth Ren
dc.contributor.authorChenevix-Trench, Georgiaen
dc.contributor.authorRahman, Nazneenen
dc.contributor.authorRobson, Marken
dc.contributor.authorDomchek, Susan Men
dc.contributor.authorFoulkes, William Den
dc.date.accessioned2016-03-08T12:19:56Z
dc.date.available2016-03-08T12:19:56Z
dc.date.issued2015-06-04en
dc.identifier.citationNew England Journal of Medicine 2015; 372:2243-2257 DOI: 10.1056/NEJMsr1501341en
dc.identifier.issn0028-4793
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/254233
dc.description.abstractAdvances in sequencing technology have made multigene testing, or “panel testing,” a practical option when looking for genetic variants that may be associated with a risk of breast cancer. In June 2013, the U.S. Supreme Court invalidated specific claims made by Myriad Genetics with respect to the patenting of the genomic DNA sequence of BRCA1 and BRCA2. Other companies immediately began to offer panel tests for breast cancer genes that included BRCA1 and BRCA2. The subsequent flourishing of gene-panel testing services has generated much interest both within the clinical genetics community and in the popular press. These panels cover a total of more than 100 genes, and breast cancer is specifically mentioned as an indication for 21 of these genes. However, the fact that the technology is available does not necessarily mean that such tests are appropriate or desirable.
dc.description.sponsorshipSupported by grants from Cancer Research UK (A11174, to Dr. Antoniou), the National Institutes of Health (CA116167, CA176785, and CA192393, to Dr. Couch), the Breast Cancer Research Foundation (to Drs. Couch, Nathanson, and Robson), Susan G. Komen (to Drs. Foulkes, Chenevix-Trench, and Domchek), the Cancer Research Society–Quebec Breast Cancer Foundation (to Dr. Foulkes), the National Health and Medical Research Council (to Dr. Chenevix-Trench), and the Basser Research Center (to Dr. Domchek).
dc.languageen_USen
dc.language.isoen_USen
dc.publisherMassachusetts Medical Society
dc.titleGene-Panel Sequencing and the Prediction of Breast-Cancer Risken
dc.typeArticle
dc.description.versionThis is the author accepted manuscript. The final version is available from The New England Journal of Medicine via http://dx.doi.org/10.1056/NEJMsr1501341en
prism.endingPage2257
prism.publicationDate2015en
prism.publicationNameThe New England Journal of Medicineen
prism.startingPage2243
prism.volume372en
dc.rioxxterms.funderCancer Research UK
dc.rioxxterms.funderNational Institutes of Health
dc.rioxxterms.funderNational Health and Medical Research Council
dc.rioxxterms.projectidA11174
dc.rioxxterms.projectidCA116167
dc.rioxxterms.projectidCA176785
dc.rioxxterms.projectidCA192393
rioxxterms.versionofrecord10.1056/NEJMsr1501341en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2015-06-04en
dc.contributor.orcidEaston, Douglas [0000-0003-2444-3247]
dc.contributor.orcidPharoah, Paul [0000-0001-8494-732X]
dc.contributor.orcidAntoniou, Antonis [0000-0001-9223-3116]
dc.contributor.orcidTischkowitz, Marc [0000-0002-7880-0628]
dc.identifier.eissn1533-4406
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idCancer Research UK (C12292/A11174)
pubs.funder-project-idCancer Research UK (10124)
pubs.funder-project-idCancer Research UK (16561)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record